NEW YORK (GenomeWeb News) – Intrinsic Bioprobes, a private clinical diagnostics developer, said today that it has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, a Johnson & Johnson company.
The blood-circulating proteins covered under the license, which were discovered using Intrinsic's mass spectrometry-based technology, have been linked with the presence of pre-diabetes and type 2 diabetes, the Tempe, Ariz.-based company said.
"The biomarkers were extensively tested and shown to have statistically significant clinical sensitivities in differentiating subjects with pre- and type-2 diabetes from healthy controls," explained Urban Kiernan, director of biomarker discovery at Intrinsic Probes.
The research leading to the discovery of these markers was funded with a five-year, $2 million grant from the National Institutes of Health, and the studies were conducted in collaboration with Yale University.
Intrinsic Bioprobes' technologies include the Mass Spectrometric Immunoassay, used for isolating proteins from complex matrices, and Bioreactive Mass Spectrometer Probes, which are used in protein characterization.
Financial terms of the agreement were not released.